ORIENTBIO Inc.
ORIENT BIO Inc. operates in the bio-industry in South Korea and internationally. It engages in the production, export, import, and life science-related research and development of laboratory animals; and offers various equipment for research environment. The company also provides infrastructural solution; health checking; generic testing; molecular biological generic testing; generic transformati… Read more
ORIENTBIO Inc. (002630) - Net Assets
Latest net assets as of September 2025: ₩69.62 Billion KRW
Based on the latest financial reports, ORIENTBIO Inc. (002630) has net assets worth ₩69.62 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩82.15 Billion) and total liabilities (₩12.53 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩69.62 Billion |
| % of Total Assets | 84.75% |
| Annual Growth Rate | 2.59% |
| 5-Year Change | 48.0% |
| 10-Year Change | -21.3% |
| Growth Volatility | 24.19 |
ORIENTBIO Inc. - Net Assets Trend (2006–2025)
This chart illustrates how ORIENTBIO Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ORIENTBIO Inc. (2006–2025)
The table below shows the annual net assets of ORIENTBIO Inc. from 2006 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₩71.85 Billion | -15.57% |
| 2024-03-31 | ₩85.10 Billion | +19.19% |
| 2023-03-31 | ₩71.39 Billion | -14.18% |
| 2022-03-31 | ₩83.19 Billion | +71.36% |
| 2021-03-31 | ₩48.55 Billion | -6.58% |
| 2020-03-31 | ₩51.96 Billion | -17.05% |
| 2019-03-31 | ₩62.65 Billion | -21.62% |
| 2018-03-31 | ₩79.92 Billion | -18.40% |
| 2017-03-31 | ₩97.94 Billion | +7.29% |
| 2016-03-31 | ₩91.29 Billion | +35.55% |
| 2015-03-31 | ₩67.35 Billion | +8.90% |
| 2014-03-31 | ₩61.85 Billion | -0.71% |
| 2013-03-31 | ₩62.29 Billion | +2.93% |
| 2012-03-31 | ₩60.51 Billion | -7.59% |
| 2011-03-31 | ₩65.49 Billion | +6.03% |
| 2010-03-31 | ₩61.77 Billion | +7.24% |
| 2009-03-31 | ₩57.60 Billion | +52.43% |
| 2008-03-31 | ₩37.79 Billion | -15.77% |
| 2007-03-31 | ₩44.86 Billion | +1.47% |
| 2006-03-31 | ₩44.21 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to ORIENTBIO Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 279135981000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩2.79 Billion | 3.89% |
| Other Components | ₩69.06 Billion | 96.11% |
| Total Equity | ₩71.85 Billion | 100.00% |
ORIENTBIO Inc. Competitors by Market Cap
The table below lists competitors of ORIENTBIO Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dynamix Corporation Warrant
NASDAQ:DYNXW
|
$28.37 Million |
|
Denali Bancorporation Inc
PINK:DENI
|
$28.39 Million |
|
Energy Solar Tech S.L.
MC:ETC
|
$28.39 Million |
|
Goodway Machine Corp
TW:1583
|
$28.40 Million |
|
Katapult Holdings Inc
NASDAQ:KPLT
|
$28.35 Million |
|
Meriaura Group Oyj
HE:MERIH
|
$28.35 Million |
|
Bougainville Copper Limited
PINK:BOCOF
|
$28.34 Million |
|
Kapsch TrafficCom AG
LSE:0GTO
|
$28.34 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ORIENTBIO Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 85,095,979,050 to 71,846,796,270, a change of -13,249,182,780 (-15.6%).
- Net loss of 13,194,865,820 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-13.19 Billion | -18.37% |
| Other Changes | ₩-54.32 Million | -0.08% |
| Total Change | ₩- | -15.57% |
Book Value vs Market Value Analysis
This analysis compares ORIENTBIO Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.90x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.58x to 0.90x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-03-31 | ₩944.23 | ₩544.00 | x |
| 2018-03-31 | ₩699.08 | ₩544.00 | x |
| 2019-03-31 | ₩636.42 | ₩544.00 | x |
| 2020-03-31 | ₩510.52 | ₩544.00 | x |
| 2021-03-31 | ₩409.47 | ₩544.00 | x |
| 2022-03-31 | ₩701.60 | ₩544.00 | x |
| 2023-03-31 | ₩602.12 | ₩544.00 | x |
| 2024-03-31 | ₩717.70 | ₩544.00 | x |
| 2025-03-31 | ₩605.95 | ₩544.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ORIENTBIO Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -18.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -44.88%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.18x
- Recent ROE (-18.37%) is below the historical average (-8.69%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 1.17% | 2.35% | 0.31x | 1.62x | ₩-3.96 Billion |
| 2011 | 7.00% | 8.44% | 0.57x | 1.46x | ₩-1.74 Billion |
| 2013 | 1.60% | 1.14% | 0.57x | 2.49x | ₩-4.60 Billion |
| 2014 | -17.36% | -11.41% | 0.60x | 2.54x | ₩-15.05 Billion |
| 2015 | -3.26% | -1.87% | 0.63x | 2.77x | ₩-7.12 Billion |
| 2016 | -3.92% | -2.86% | 0.60x | 2.29x | ₩-10.69 Billion |
| 2017 | -27.21% | -17.54% | 0.63x | 2.46x | ₩-26.16 Billion |
| 2018 | -26.30% | -11.44% | 0.64x | 3.60x | ₩-19.14 Billion |
| 2019 | -30.11% | -64.22% | 0.36x | 1.30x | ₩-25.98 Billion |
| 2020 | -20.94% | -28.86% | 0.52x | 1.39x | ₩-16.08 Billion |
| 2021 | -31.47% | -29.36% | 0.73x | 1.47x | ₩-20.13 Billion |
| 2022 | 41.11% | 130.15% | 0.25x | 1.26x | ₩25.88 Billion |
| 2023 | -17.40% | -43.11% | 0.36x | 1.14x | ₩-19.56 Billion |
| 2024 | 15.13% | 45.96% | 0.29x | 1.14x | ₩4.36 Billion |
| 2025 | -18.37% | -44.88% | 0.35x | 1.18x | ₩-20.38 Billion |
Industry Comparison
This section compares ORIENTBIO Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $280,543,820,050
- Average return on equity (ROE) among peers: 0.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ORIENTBIO Inc. (002630) | ₩69.62 Billion | 1.17% | 0.18x | $28.37 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $229.70 Million |
| Green Cross Holdings Preference Shares (005257) | $1.88 Trillion | -2.88% | 0.99x | $409.02 Million |
| Pharmicell (005690) | $76.66 Billion | 10.78% | 0.43x | $453.92 Million |
| GeneOne Life Science Inc (011000) | $23.71 Billion | -35.27% | 0.34x | $52.94 Million |
| Daesung Microbiological Labs. Co. Ltd (036480) | $19.73 Billion | 2.26% | 0.29x | $14.76 Million |
| Seoulin Bioscience Co.Ltd (038070) | $59.92 Billion | 8.17% | 0.31x | $27.84 Million |
| Hyundai Bioscience Co. Ltd (048410) | $60.94 Billion | 0.00% | 2.69x | $964.67 Million |
| iNtRON Biotechnology Inc (048530) | $49.15 Billion | -1.24% | 0.21x | $83.99 Million |
| Synergy Innovation Co. Ltd (048870) | $71.09 Billion | 0.00% | 0.77x | $77.78 Million |